LivaNova (LIVN) Q1 Earnings and Revenues Surpass Estimates

Core Viewpoint - LivaNova reported quarterly earnings of $0.88 per share, exceeding the Zacks Consensus Estimate of $0.75 per share, and showing an increase from $0.73 per share a year ago, representing a 17.33% earnings surprise [1][2] Financial Performance - The company achieved revenues of $316.9 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 5.41%, and up from $294.9 million year-over-year [2] - Over the last four quarters, LivaNova has consistently surpassed consensus EPS estimates four times and revenue estimates three times [2] Stock Performance - LivaNova shares have declined approximately 24.1% since the beginning of the year, contrasting with the S&P 500's decline of 4.7% [3] - The current Zacks Rank for LivaNova is 4 (Sell), indicating expectations of underperformance in the near future [6] Future Outlook - The consensus EPS estimate for the upcoming quarter is $1.01 on revenues of $331.03 million, and for the current fiscal year, it is $3.65 on revenues of $1.3 billion [7] - The outlook for the Medical - Instruments industry is favorable, ranking in the top 35% of over 250 Zacks industries, suggesting potential for better performance compared to lower-ranked industries [8]